Gemini Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November: Stifel 2021 Virtual Healthcare Conference Date: Monday, November 15, 2021 Time: 8:40 AM ET Jefferies London
Click here to view original post